BioNTech Spends $205 Million on an FDA Fast Lane as Patent Claims Pile Up on Two Continents
Published on 11/20/2026 at 10:31 | Editorial boerse-global.deJPMorgan nudged its price target on BioNTech higher yesterday, lifting the figure to US$93 from US$92 while keeping its "Neutral" rating on the shares. The modest revision landed as the stock traded at 73.55 € on Friday, down 0.9%, after closing at 74.20 € the previous session following a 2.1% decline.
The Mainz-based biotech's more consequential move came last week, when it struck a deal with Scholar Rock Holding Corporation to acquire a priority review voucher from the US Food and Drug Administration. The cash purchase price is set at US$205 million, and BioNTech intends to deploy the voucher on a future marketing application for a candidate drawn from its late-stage oncology pipeline. Completion hinges on customary closing conditions, including clearance under the Hart-Scott-Rodino review process.
Oncology Push Continues Alongside the Voucher Deal
BioNTech's cancer ambitions were on display on 22 October, when the company and Gilead Sciences advanced a Phase 3 trial in triple-negative breast cancer. The study is evaluating Pumitamig in combination with Gilead's Sacituzumab Govitecan.
Should investors sell immediately? Or is it worth buying BioNTech?
Legal Front Widens in Canada and Japan
On the intellectual property side, Arbutus Biopharma and Genevant Sciences expanded their patent litigation against Pfizer, BioNTech and affiliated entities last Friday. The plaintiffs added a newly granted lipid nanoparticle patent to their existing Canadian action, arguing that patents tied to COVID-19 vaccines have been infringed. They are seeking damages and an injunction.
The same pair also filed two additional patent suits against Pfizer Japan in Tokyo. The claims target technology used in the COVID-19 vaccines developed by Pfizer and BioNTech.
Ad
BioNTech Stock: New Analysis - 20 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
